Aly A, Singh P, Korytowsky B, Ling Y-L, Kale HP, Dastani HB, Botteman MF, Norden AD (2020) Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. Neuro-Oncol Pract 7:164–175

Google Scholar 

Wank M, Schilling D, Schmid TE, Meyer B, Gempt J, Barz M, Schlegel J, Liesche F, Kessel KA, Wiestler B et al (2018) Human Glioma Migration and Infiltration Properties as a target for Personalized Radiation Medicine. Cancers 10:456

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

Article  CAS  PubMed  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820

Article  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro-Oncol 23:1231–1251

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T (2001) Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 52:161–171

Article  CAS  PubMed  Google Scholar 

Gittlemann H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS (2019) An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neurooncol Adv 1:1–9

Google Scholar 

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, Aldape KD, Lhermitte B, Pietsch T, Grujicic D et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071– 22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108

Article  CAS  PubMed  Google Scholar 

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715

Article  CAS  PubMed  Google Scholar 

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U et al (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in newly diagnosed O6-Methylguanine-DNA methyltransferase nonmethylated Glioblastoma: the Randomized GLARIUS Trial. J Clin Oncol off J Am Soc Clin Oncol 34:1611–1619

Article  CAS  Google Scholar 

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet Lond Engl 393:678–688

Article  CAS  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

Article  CAS  PubMed  Google Scholar 

Ening G, Osterheld F, Capper D, Schmieder K, Brenke C (2015) Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol 141:1131–1137

Article  CAS  PubMed  Google Scholar 

Schneider M, Plotthoff AL, Scharnböck E, Heimann M, Schäfer N, Weller J, Schaub C, Jacobs AH, Güresir E, Herrlinger U, Vatter H, Schuss P (2020) Newly diagnosed glioblastoma in geriatric (65+) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. J Neurooncol 149:421–427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barz M, Bette S, Janssen I, Aftahy AK, Huber T, Liesche-Starnecker F, Ryang YM, Wiestler B, Combs SE, Meyer B, Gempt J (2022) Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor? BMC Neurol 22:32

Article  PubMed  PubMed Central  Google Scholar 

Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8

Article  PubMed  Google Scholar 

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J, ALA-Glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401

Article  CAS  PubMed  Google Scholar 

Stummer W, Reulen H-J, Meinel T, Pichlmeier U, Schumacher W, Tonn J-C, Rohde V, Oppel F, Turowski B, Woiciechowsky C et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576

Article  PubMed  Google Scholar 

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198

Article  CAS  PubMed  Google Scholar 

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G et al (2007) Long-term survival with glioblastoma multiforme. Brain J Neurol 130:2596–2606

Article  Google Scholar 

Kreth F-W, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M et al (2013) Gross total but not incomplete resection of Glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol off J Eur Soc Med Oncol 24:3117–3123

Article  Google Scholar 

Ius T, Pignotti F, Della Pepa GM, La Rocca G, Somma T, Isola M, Battistella C, Gaudino S, Polano M, Dal Bo M et al (2020) A Novel Comprehensive Clinical Stratification Model to refine prognosis of Glioblastoma patients Undergoing Surgical Resection. Cancers 12:386

Article  PubMed  PubMed Central  Google Scholar 

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Philips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037

Article  CAS  PubMed  Google Scholar 

Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

Article  PubMed  Google Scholar 

Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569

Article  CAS  PubMed  Google Scholar 

Pichlmeier U, Bink A, Schackert G, Stummer W, ALA Glioma Study Group (2008) Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10:1025–1034

Article  PubMed  PubMed Central  Google Scholar 

Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH (2017) Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promotor methylation and IDH1 gene mutation status. Radiother Oncol 123:106–111

Article  CAS  PubMed  Google Scholar 

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A (2017) Molecular-based recursive partitioning analysis (RPA) model for glioblastoma in the temozolomide era: a correlative analysis based upon NRG Oncology RTOG 0525. JAMA Oncol 3:784–792

Article  PubMed  PubMed Central  Google Scholar 

Woo P, Ho J, Lam S, Ma E, Chan D, Wong WK, Mak C, Lee M, Wong ST, Chan KY, Poon WS (2018) A comparative analysis of the usefulness of survival prediction models for patients with glioblastoma in the temozolomide era: the importance of methylguanine methyltransferase promotor methylation, extent of resection, and subventricular zone location. World Neurosurg 115:e375–e385

Article  PubMed